GSK and Flagship Pioneering said the collaboration will start by identifying the most “promising scientific concepts” from Flagship’s portfolio of 40 companies, which includes pharmaceutical giants like Moderna and Omega Therapeutics.
Initial Funding and Development
The two companies have committed to jointly fund an initial injection of $150 million for Flagship’s portfolio of companies. This funding will assist in the “exploration phase” of the companies’ most promising projects and ideas, initially focusing on respiratory and immunology fields.
GSK will hold an exclusive option over the 10 selected research projects for potential future clinical development. In addition to the $720 million from GSK, the chosen medicines and vaccines will also be entitled to preclinical funding and tiered royalties.
GSK To Put Up To $7.2B Into Biotech VC’s Pipeline : Shared Focus on Innovation
Flagship’s general partner, Paul Biondi, emphasized the two companies’ “shared focus” on delivering pioneering medicines.